The identification of the mobile receptor utilized by viruses to enter their goal cells is all the time a problem and so far entry receptors stay to be recognized for quite a lot of pathogenic human viruses. Human T-lymphotropic virus sort 1 (HTLV-1), the distinctive oncogenic retrovirus in human, was recognized within the early 1980 ‘s.
The character of its entry receptor has remained a thriller for over 20 years, till the unbiased identification of three proteins presenting the anticipated standards, the glucose transporter Glut1, Neuropilin 1, a VEGF receptor, and heparan sulfate proteoglycans. On this overview, we summarize the information pertaining to HTLV-1 entry molecules and current a brand new mannequin, during which these three proteins successively intervene in the course of the entry course of.

Protecting efficacy of rhesus adenovirus COVID-19 vaccines in opposition to mouse-adapted SARS-CoV-2

The speedy design and implementation of extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is testomony to a efficiently coordinated international analysis effort. Whereas using quite a lot of totally different applied sciences, a few of which have been used for the primary time, all authorized vaccines show excessive ranges of efficacy with glorious security profiles.
Regardless of this, there stays an pressing international demand for coronavirus illness 2019 vaccines that require additional candidates to move part three medical trials. Within the expectation of SARS-CoV-2 changing into endemic, researchers want to alter the vaccine constructs to sort out rising variants.
On this overview, we define totally different platforms used for authorized vaccines and summarize newest analysis information close to immunogenicity, dosing regimens and effectivity in opposition to rising variants.
Les récepteurs d'entrée du HTLV-1 : un ménage à trois

A Multiplex Noninvasive Salivary Antibody Assay for SARS-CoV-2 An infection and Its Utility in a Inhabitants-Primarily based Survey by Mail

Noninvasive salivary antibody immunoassays can allow low-cost epidemiological surveillance of infections. This research concerned growing and validating a multiplex suspension immunoassay on the Luminex platform to measure immunoglobulin G (IgG) responses to extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid and spike (S) proteins, and the spike protein’s S1 and S2 subunits and receptor binding area.
A number of variations of those recombinant proteins acquired from industrial and noncommercial sources have been evaluated. Assay improvement and validation utilized saliva and serum samples from coronavirus illness 2019 (COVID-19) circumstances procured from industrial sources and adverse controls from a prepandemic survey.
Saliva was additionally collected in an indication survey by mail involving grownup people in america who have been recognized with SARS-CoV-2 an infection 15 to 80 days previous to pattern assortment. The survey had an 83% legitimate pattern return price (192 samples from 38 states). Most COVID-19 circumstances (93%) reported mildly symptomatic or asymptomatic infections.
The ultimate salivary assay based mostly on the best-performing spike and nucleocapsid proteins had a sensitivity of 87.1% (95% bootstrap confidence interval, 82.1 to 91.7%) and specificity of 98.5% (95.Zero to 100%) utilizing 227 and 285 saliva samples, respectively.
The identical assay had 95.9% (92.eight to 98.9%) sensitivity and 100% (98.four to 100%) specificity in serum (174 and 285 serum samples, respectively). Salivary and serum antibody responses to spike and nucleocapsid proteins have been strongly correlated in 22 paired samples (r = 0.88 and r = 0.80, respectively).
Antibody responses peaked at roughly 50 days postonset; better sickness severity was related to stronger responses. This research demonstrated {that a} salivary antibody assay can be utilized in large-scale inhabitants surveys by mail to raised characterize public well being impacts of COVID-19. IMPORTANCE Given the large impacts of the COVID-19 pandemic, growing instruments for inhabitants surveillance of an infection is of paramount significance.
This text describes the event of a multiplex immunoassay on a Luminex platform to measure salivary immunoglobulin G responses to the spike protein, its two subunits and receptor binding area, and the nucleocapsid protein of SARS-CoV-2. The assay validation utilized serum and saliva samples from prepandemic controls and up to date COVID-19 circumstances.
A survey by mail focusing on latest COVID-19 circumstances throughout america additionally demonstrated the utility of protected, at-home self-collection of saliva. By incorporating a number of SARS-CoV-2 proteins, this assay might differentiate responses to pure SARS-CoV-2 infections from responses to most vaccines.
Utility of this noninvasive immunoassay in COVID-19 surveillance can assist present estimates of cumulative incidence charges of symptomatic and asymptomatic infections in numerous communities and subpopulations, temporal patterns of antibody responses, and threat components for an infection.

Uncared for roles of IgG Fc-binding protein secreted from airway mucin-producing cells in defending in opposition to SARS-CoV-2 an infection

Each innate immunity and purchased immunity are concerned in extreme acute respiratory syndrome coronavirus-2 (SARS-CoV-2) an infection. The induction of Abs that neutralize the virus has been described, and sure Abs in opposition to endemic coronaviruses might cross-react with SARS-CoV-2. Detailed mechanisms to guard in opposition to the pandemic of SARS-CoV-2 stay unresolved.
We beforehand reported that IgG Fc-binding protein (Fcγbp), a novel, massive molecular weight, and mucin-like secretory Fc receptor protein, secreted from goblet cells of human small and enormous gut, mediates the transportation of serum IgG onto the mucosal floor.
On this overview, we present that mucous bronchial gland cells and a few goblet cells are immunoreactive for Fcγbp. Fcγbp traps the cross-reactive (each neutralizing and non-neutralizing) IgG certain to the virus and may consequently remove the virus from the mucosal floor to lower viral hundreds.
Fcγbp may suppress immune overreaction by interfering with Fc-binding by macrophages and competing with complement fixation. Fcγbp secreted from mucin-producing cells of the airway capabilities as an necessary anti-infection mucosal protection. The Fcγbp-mediated mechanism could be a key think about explaining why SARS-CoV-2 is much less infective/deadly in youngsters, and may be concerned within the distinctive Ab response, recurrent an infection, and results of serum remedy and vaccination.

Protecting efficacy of rhesus adenovirus COVID-19 vaccines in opposition to mouse-adapted SARS-CoV-2

The worldwide COVID-19 pandemic has sparked intense curiosity within the speedy improvement of vaccines in addition to animal fashions to guage vaccine candidates and to outline immune correlates of safety. We lately reported a mouse-adapted SARS-CoV-2 virus pressure (MA10) with the potential to contaminate wild-type laboratory mice, driving excessive ranges of viral replication in respiratory tract tissues in addition to extreme medical and respiratory signs, points of COVID-19 illness in people which are necessary to seize in mannequin techniques.
We evaluated the immunogenicity and protecting efficacy of novel rhesus adenovirus serotype 52 (RhAd52) vaccines in opposition to MA10 problem in mice. Baseline seroprevalence is decrease for rhesus adenovirus vectors than for human or chimpanzee adenovirus vectors, making these vectors enticing candidates for vaccine improvement.
We noticed that RhAd52 vaccines elicited sturdy binding and neutralizing antibody titers, which inversely correlated with viral replication after problem. These information help the event of RhAd52 vaccines and the usage of the MA10 problem virus to display screen novel vaccine candidates and to review the immunologic mechanisms that underscore safety from SARS-CoV-2 problem in wild-type mice.
Significance We have now developed a sequence of SARS-CoV-2 vaccines utilizing rhesus adenovirus serotype 52 (RhAd52) vectors, which reveals a decrease seroprevalence than human and chimpanzee vectors, supporting their improvement as novel vaccine vectors or in its place Advert vector for enhancing.
We sought to check these vaccines utilizing a lately reported mouse-adapted SARS-CoV-2 (MA10) virus to i) consider the protecting efficacy of RhAd52 vaccines and ii) additional characterize this mouse-adapted problem mannequin and probe immune correlates of safety.

Recombinant SARS SARS Mosaic S(M) Protein, Untagged, E.coli-1mg
QP13421-1mg 1mg
EUR 1273.2

Recombinant SARS SARS Mosaic S(M) Protein, Untagged, E.coli-500ug
QP13421-500ug 500ug
EUR 795.6

Recombinant SARS SARS Mosaic S(N) Protein, Untagged, E.coli-100ug
QP13422-100ug 100ug
EUR 261.6

Recombinant SARS SARS Mosaic S(N) Protein, Untagged, E.coli-1mg
QP13422-1mg 1mg
EUR 1273.2

Recombinant SARS SARS Mosaic S(N) Protein, Untagged, E.coli-500ug
QP13422-500ug 500ug
EUR 795.6

SARS Associated Spike Mosaic S(M) Protein
20-abx260155
  • EUR 1062.00
  • EUR 410.40
  • EUR 1646.40
  • 0.5 mg
  • 100 ug
  • 1 mg

SARS Associated Spike Mosaic S(N) Protein
20-abx260157
  • EUR 1062.00
  • EUR 410.40
  • EUR 1646.40
  • 0.5 mg
  • 100 ug
  • 1 mg

(S)-Crizotinib
A8802-S Evaluation Sample
EUR 97.2
Description: (S)-crizotinibthe selectively inhibited MTH1 catalytic activity with IC50 of 72 nM, while clinically used (R)-enantiomer of the drug was inactive with IC50 of 1375 nM.

Demeton S
S-1141 1ML
EUR 131.1

SARS-CoV S Recombinant Protein (R667A, K968P, V969P)
11-115 0.1 mg
EUR 884.4
Description: It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Recombinant SARS S Protein (aa 1-1190) [His]
VAng-Lsx0060-inquire inquire Ask for price
Description: SARS Surface Antigen (aa 1-1190) [His], recombinant protein from HEK 293 cells.

Recombinant SARS Spike Mosaic Protein S (N-Terminal)
VAng-Lsx0073-inquire inquire Ask for price
Description: SARS spike mosaic protein S (N-terminal), recombinant protein from E. coli.

SARS-CoV-2 S Recombinant Antibody, HRP Conjugated
A73673-050 50 ul
EUR 377.3

SARS-CoV-2 S Recombinant Antibody, HRP Conjugated
A73673-100 100 ul
EUR 518.1

SARS-CoV-2 S Recombinant Antibody, FITC Conjugated
A73674-050 50 ul
EUR 377.3

SARS-CoV-2 S Recombinant Antibody, FITC Conjugated
A73674-100 100 ul
EUR 518.1

SARS-CoV-2 S Recombinant Antibody, Biotin Conjugated
A73675-050 50 ul
EUR 377.3

SARS-CoV-2 S Recombinant Antibody, Biotin Conjugated
A73675-100 100 ul
EUR 518.1

SARS-CoV-2 S Recombinant Antibody, HRP Conjugated
A73673
  • EUR 377.30
  • EUR 518.10
  • 50 ul
  • 100 ul

SARS-CoV-2 S Recombinant Antibody, FITC Conjugated
A73674
  • EUR 377.30
  • EUR 518.10
  • 50 ul
  • 100 ul

SARS-CoV-2 S Recombinant Antibody, Biotin Conjugated
A73675
  • EUR 377.30
  • EUR 518.10
  • 50 ul
  • 100 ul

Recombinant SARS Associated Spike Mosaic S(N)
7-07093 100µg Ask for price

Recombinant SARS Associated Spike Mosaic S(N)
7-07094 500µg Ask for price

Recombinant SARS Associated Spike Mosaic S(N)
7-07095 1000µg Ask for price

Recombinant SARS Associated Spike Mosaic S(M)
7-07096 100µg Ask for price

Recombinant SARS Associated Spike Mosaic S(M)
7-07097 500µg Ask for price

Recombinant SARS Associated Spike Mosaic S(M)
7-07098 1000µg Ask for price

Recombinant SARS Associated Spike Mosaic S©
7-07099 100µg Ask for price

Recombinant SARS Associated Spike Mosaic S©
7-07100 500µg Ask for price

Recombinant SARS Associated Spike Mosaic S©
7-07101 1000µg Ask for price

Recombinant (E.Coli) SARS Associated Spike Mosaic S
RP-1422 100 ug
EUR 343.2

Recombinant (E.Coli) SARS Associated Spike Mosaic S
RP-1423 100 ug
EUR 343.2

Recombinant (E.Coli) SARS Associated Spike Mosaic S
RP-1424 100 ug
EUR 343.2

SARS-CoV-2 (COVID-19) S-trimer Recombinant Protein
11-070 0.1 mg
EUR 695.4
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S Recombinant Protein RBD
11-215 0.2 mg
EUR 1086
Description: It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S RBD Recombinant Protein
10-413 0.1 mg
EUR 714.3
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S RBD Recombinant Protein
10-431 0.1 mg
EUR 714.3
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S RBD Recombinant Protein
97-093 0.1 mg
EUR 714.3
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, DPP4, CEACAM etc.. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Recombinant Coronavirus Spike Protein (SARS-CoV S, His tag)
P1520-10 10µg
EUR 308.4

Demeton (O and S)
S-1140 1ML
EUR 71.82

SARS-CoV-2 (COVID-19) S Protein RBD Recombinant Protein
10-433 0.1 mg
EUR 714.3
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S Protein NTD Recombinant Protein
92-738 0.05 mg
EUR 468.6
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S Protein HR1 Recombinant Protein
92-760 0.05 mg
EUR 468.6
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. After binding of RBD in S1 subunit of S protein on the virion to the ACE2 receptor on the target cell, the heptad repeat 1 (HR1) and 2 (HR2) domains in its S2 subunit of S protein interact with each other to form a six-helix bundle (6-HB) fusion core, bringing viral and cellular membranes into close proximity for fusion and infection. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S Protein HR1 Recombinant Protein
92-761 0.05 mg
EUR 468.6
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. After binding of RBD in S1 subunit of S protein on the virion to the ACE2 receptor on the target cell, the heptad repeat 1 (HR1) and 2 (HR2) domains in its S2 subunit of S protein interact with each other to form a six-helix bundle (6-HB) fusion core, bringing viral and cellular membranes into close proximity for fusion and infection. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 Spike Glycoprotein Expression (S) Lentivector, pCDH-CMV-SARS-CoV-2-S-EF1α-Puro (Plasmid)
CVD19-130PA-1 10 µg
EUR 728

SARS Antibody
1-CSB-PA020709GA01HU
  • EUR 716.40
  • EUR 399.60
  • 150ul
  • 50ul
Description: A polyclonal antibody against SARS. Recognizes SARS from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC

SARS Antibody
1-CSB-PA04145A0Rb
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against SARS. Recognizes SARS from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:1000-1:5000, IHC:1:20-1:200

SARS Antibody
DF15539 100ul
EUR 420

SARS antibody
70R-20086 50 ul
EUR 522
Description: Rabbit polyclonal SARS antibody

SARS antibody
70R-1444 100 ug
EUR 452.4
Description: Rabbit polyclonal SARS antibody raised against the C terminal of SARS

SARS antibody
70R-1445 100 ug
EUR 452.4
Description: Rabbit polyclonal SARS antibody raised against the middle region of SARS

SARS antibody
39139-100ul 100ul
EUR 302.4

SARS N Protein Antibody
abx018255-100ug 100 ug
EUR 460.8

SARS N Protein Antibody
abx018256-100ug 100 ug
EUR 460.8

SARS-CoV-2 (COVID-19) Spike S Trimer Recombinant Protein
20-182 0.1 mg
EUR 651.3
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S-trimer 6P Recombinant Protein
11-068 0.1 mg
EUR 714.3
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S + M + E Recombinant Protein
11-071 0.1 mg
EUR 695.4
Description: Coronavirus envelope (E) proteins are short (100 residues) polypeptides that contain at least one transmembrane (TM) domain and a cluster of 2-3 juxtamembrane cysteines. These proteins are involved in viral morphogenesis and tropism, and their absence leads in some cases to aberrant virions, or to viral attenuation. In common to other viroporins, coronavirus envelope proteins increase membrane permeability to ions, plays a central role in virus morphogenesis and assembly. Acts as a viroporin and self-assembles in host membranes forming pentameric protein-lipid pores that allow ion transport. Also plays a role in the induction of apoptosis. Activates the host NLRP3 inflammasome, leading to IL-1beta overproduction.

SARS-CoV-2 (COVID-19) Trimeric Spike (S) Recombinant Protein
10-075 0.1 mg
EUR 991.5
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The S protein is a transmembrane, homotrimeric, class I fusion glycoprotein that mediates viral attachment, fusion, and entry into host cells 3. Each ~180 kDa monomer contains two functional subunits, S1 (~700 a.a) and S2 (~600 a.a), that mediate viral attachment and membrane fusion, respectively. S1 contains two major domains, the N-terminal (NTD) and C-terminal domains (CTD). The CTD contains the receptor-binding domain (RBD), which binds to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells 3-5. Although both SARS-CoV and SARS-CoV-2 bind the ACE2 receptor, the RBDs only share ~73% amino acid identity, and the SARS-CoV-2 RBD binds with a higher affinity compared to SARS-CoV 3, 6. The RBD is dynamic and undergoes hinge-like conformational changes, referred to as the “down” or “up” conformations, which hide or expose the receptor-binding motifs, respectively 7. Following receptor binding, S1 destabilizes, and TMPRSS2 cleaves S2, which undergoes a pre- to post-fusion conformation transition, allowing for membrane fusion 8, 9. The S protein has been the main focus of therapeutic and vaccine design as it is highly immunogenic. Both neutralizing antibodies 10,11 and memory T cells 12,13 targeting the S protein are present in the sera of convalescent COVID-19 patients.

SARS-CoV-2 (COVID-19) S-trimer (D614G) Recombinant Protein
92-748 0.05 mg
EUR 619.8
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell atthe advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acuterespiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusionrequired for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's beenreported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the humanACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor.S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction ofneutralizing-antibody and T-cell responses, as well as protective immunity.

Rabbit Anti-flagellin protein (Fla/FLGN, S. typhimurium) antiserum
FLGN12-S 100 ul
EUR 562.8

SARS-CoV-2 (COVID-19) S Protein RBD-SD1 Recombinant Protein
92-736 0.05 mg
EUR 468.6
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S Protein RBD-SD1 Recombinant Protein
92-737 0.02 mg
EUR 556.8
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S Protein RBD (N501Y) Recombinant Protein
92-762 0.05 mg
EUR 569.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S Protein RBD (N501Y) Recombinant Protein
92-763 0.05 mg
EUR 569.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 Spike Glycoprotein (S) Expression Lentivector, pCDH-CMV-SARS-CoV-2-S-EF1α-Puro (Pre-packaged Lentivirus)
CVD19-130VA-1 >2x10^6 IFUs
EUR 728

Recombinant SARS-CoV-2 Spike Glycoprotein(S) (D614G), Partial
E80028-1 20 ul
EUR 388.3

Recombinant SARS-CoV-2 Spike Glycoprotein(S) (D614G), Partial
E80028-2 100 ul
EUR 860.2

Recombinant SARS-CoV-2 Spike Glycoprotein(S) (D614G), Partial
E80028
  • EUR 388.30
  • EUR 860.20
  • 20 ul
  • 100 ul

Recombinant SARS Spike Mosaic S Protein (aa 408-470, 540-573)
VAng-Lsx0056-inquire inquire Ask for price
Description: Recombinant SARS-CoV Spike protein containing 408-470, 540-573 amino acids immunodominant regions was expressed in E. coli and purified by proprietary chromatographic technique.

Bisphenol S 1000 ug/mL in Methanol
S-5871 1ML
EUR 109.44

1000 ug/mL (S)-(-)-Limonene in Ethanol
S-6409 1ML
EUR 88.92

SARS-CoV spike protein Antibody
abx023139-100ug 100 ug
EUR 1028.4

SARS-CoV spike protein Antibody
abx023143-100ug 100 ug
EUR 1028.4

SARS Conjugated Antibody
C39139 100ul
EUR 476.4

anti- SARS antibody
FNab07609 100µg
EUR 658.5
Description: Antibody raised against SARS

SARS Spike Antibody
24216-100ul 100ul
EUR 468

SARS Spike Antibody
24217-100ul 100ul
EUR 468

SARS Spike Antibody
24218-100ul 100ul
EUR 468

SARS Spike Antibody
24219-100ul 100ul
EUR 468

SARS Spike Antibody
24318-100ul 100ul
EUR 468

SARS Matrix Antibody
24319-100ul 100ul
EUR 468

SARS Matrix Antibody
24320-100ul 100ul
EUR 468

SARS Envelope Antibody
24321-100ul 100ul
EUR 468

SARS Envelope Antibody
24322-100ul 100ul
EUR 468

SARS Coronavirus antibody
10C-CR9003M1 100 ug
EUR 598.8
Description: Mouse monoclonal SARS Coronavirus antibody

SARS Nucleocapsid antibody
10R-10470 100 ug
EUR 522
Description: Mouse monoclonal SARS Nucleocapsid antibody

SARS Nucleocapsid antibody
10R-10471 100 ug
EUR 522
Description: Mouse monoclonal SARS Nucleocapsid antibody

SARS E2 antibody
10R-1976 100 ul
EUR 289.2
Description: Mouse monoclonal SARS E2 antibody

SARS M antibody
10R-1977 100 ul
EUR 289.2
Description: Mouse monoclonal SARS M antibody

SARS Spike Antibody
20-abx137184
  • EUR 1262.40
  • EUR 1846.80
  • EUR 2064.00
  • 100 ug
  • 200 ug
  • 300 µg

SARS Nucleocapsid Antibody
20-abx137185
  • EUR 1262.40
  • EUR 1846.80
  • EUR 2364.00
  • 100 ug
  • 200 ug
  • 300 µg

SARS Spike Antibody
20-abx137200
  • EUR 1412.40
  • EUR 2264.40
  • EUR 2665.20
  • 100 ug
  • 200 ug
  • 300 µg

SARS Nucleocapsid Antibody
20-abx137201
  • EUR 1412.40
  • EUR 2264.40
  • EUR 2665.20
  • 100 ug
  • 200 ug
  • 300 µg

SARS-E2 Antibody
abx016055-100ul 100 ul
EUR 493.2

SARS-M Antibody
abx016056-100ul 100 ul
EUR 493.2

Anti-SARS antibody
PAab07609 100 ug
EUR 463.2

Anti-SARS antibody
STJ28816 100 µl
EUR 332.4
Description: This gene belongs to the class II amino-acyl tRNA family. The encoded enzyme catalyzes the transfer of L-serine to tRNA (Ser) and is related to bacterial and yeast counterparts. Multiple alternatively spliced transcript variants have been described but the biological validity of all variants is unknown.

Anti-SARS antibody
STJ115313 100 µl
EUR 332.4
Description: This gene belongs to the class II amino-acyl tRNA family. The encoded enzyme catalyzes the transfer of L-serine to tRNA (Ser) and is related to bacterial and yeast counterparts. Multiple alternatively spliced transcript variants have been described but the biological validity of all variants is unknown.

SARS Polyclonal Antibody
A71293-050 50 ul
EUR 302.5

SARS Polyclonal Antibody
A71293-100 100 ul
EUR 423.5

SARS Polyclonal Antibody
A53977-020 20 ul
EUR 117.7

SARS Polyclonal Antibody
A53977-050 50 ul
EUR 302.5

SARS Polyclonal Antibody
A53977-100 100 ul
EUR 423.5

SARS Polyclonal Antibody
A53977
  • EUR 684.66
  • EUR 117.70
  • EUR 302.50
  • EUR 423.50
  • 100 µg
  • 20 ul
  • 50 ul
  • 100 ul

SARS Polyclonal Antibody
A71293
  • EUR 302.50
  • EUR 423.50
  • 50 ul
  • 100 ul

Sars/ Rat Sars ELISA Kit
ELI-41050r 96 Tests
EUR 1063.2

Protein S antibody
70R-6073 50 ug
EUR 560.4
Description: Rabbit polyclonal Protein S antibody

Protein S antibody
70R-10600 500 ug
EUR 584.4
Description: Affinity purified sheep polyclonal Protein S antibody

Protein S antibody
70R-13274 100 ul
EUR 548.4
Description: Affinity purified Rabbit polyclonal Protein S antibody

Protein S antibody
22939-100ul 100ul
EUR 468

Protein S antibody
20R-1388 5 mg
EUR 330
Description: Goat polyclonal Protein S antibody

Protein S antibody
20R-1389 10 mg
EUR 330
Description: Sheep polyclonal Protein S antibody

Rabbit Anti-Sm28/Smp28/GST28/GST-mu protein (S. Japonicum, 1-211aa) antiserum
SM282-S 100 ul
EUR 548.4

Recombinant SARS SARS Core Protein, Untagged, E.coli-100ug
QP10499-100ug 100ug
EUR 261.6

Recombinant SARS SARS Core Protein, Untagged, E.coli-1mg
QP10499-1mg 1mg
EUR 1273.2

Recombinant SARS SARS Core Protein, Untagged, E.coli-500ug
QP10499-500ug 500ug
EUR 795.6

Recombinant SARS SARS Core Protein, Untagged, E.coli-100ug
QP13416-100ug 100ug
EUR 261.6

Recombinant SARS SARS Core Protein, Untagged, E.coli-1mg
QP13416-1mg 1mg
EUR 1273.2

Recombinant SARS SARS Core Protein, Untagged, E.coli-500ug
QP13416-500ug 500ug
EUR 795.6

Recombinant SARS SARS Envelope Protein, Untagged, E.coli-100ug
QP13417-100ug 100ug
EUR 261.6

Recombinant SARS SARS Envelope Protein, Untagged, E.coli-1mg
QP13417-1mg 1mg
EUR 1273.2

Recombinant SARS SARS Envelope Protein, Untagged, E.coli-500ug
QP13417-500ug 500ug
EUR 795.6

Recombinant SARS SARS Matrix Protein, Untagged, E.coli-100ug
QP13418-100ug 100ug
EUR 261.6

Recombinant SARS SARS Matrix Protein, Untagged, E.coli-1mg
QP13418-1mg 1mg
EUR 1273.2

Recombinant SARS SARS Matrix Protein, Untagged, E.coli-500ug
QP13418-500ug 500ug
EUR 795.6

Recombinant SARS SARS MERS Protein, His, E.coli-100ug
QP13419-100ug 100ug
EUR 261.6

Recombinant SARS SARS MERS Protein, His, E.coli-1mg
QP13419-1mg 1mg
EUR 1513.2

Recombinant SARS SARS MERS Protein, His, E.coli-500ug
QP13419-500ug 500ug
EUR 795.6

Recombinant SARS SARS-CoV Protein, His, E.coli-1mg
QP13423-1mg 1mg
EUR 4744.8

Recombinant SARS SARS-CoV Protein, His, E.coli-20ug
QP13423-20ug 20ug
EUR 241.2

Recombinant SARS SARS-CoV Protein, His, E.coli-5ug
QP13423-5ug 5ug
EUR 186

SARS-CoV-2 (COVID-19) S1+S2 ECD (S-ECD) Recombinant Protein
10-108 0.1 mg
EUR 1186.8
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses as well as protective immunity.

SARS-CoV-2 (COVID-19) S1+S2 ECD (S-ECD) Recombinant Protein
10-121 0.1 mg
EUR 1186.8
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses as well as protective immunity.

pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix
CVD19-500A-1 10 rxn
EUR 677

pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix
CVD19-510A-1 25 rxn
EUR 1349

Rabbit Anti-S. Pneumococcal Serotype 23F Carbohydrate (Spn23F) Antiserum
SPN231-S 100 ul
EUR 534

1000ug/mL of S-Metolachlor in Acetonitrile 1mL ampule
S-5203 1ML
EUR 328.32

SARS Nucleocapsid Recombinant Protein
10-213 0.1 mL
EUR 752.1
Description: The nucleocapsid (N) protein of SARS-coronavirus (SARS-CoV) is the key protein for the formation of the helical nucleocapsid during virion assembly. The nucleocapsid (N) protein of SARS-CoV enters the host cell together with the viral RNA and interferes with several cellular processes. Some of these processes involve interactions between SARS-CoV N protein and host- cell proteins. It has also been demonstrated that the SARS-CoV N protein can bind to DNA in vitro. These interactions might have a role in the pathology of SARS. The N protein may be of potential value in vaccine development for specific prophylaxis and treatment against SARS.

SARS CoV E Protein
abx060650-1mg 1 mg
EUR 2030.4

SARS CoV Nucleocapsid Protein
abx060652-1mg 1 mg
EUR 2247.6

SARS-CoV Nucleocapsid Protein
abx060653-1mg 1 mg
EUR 2030.4

SARS-CoV Nucleocapsid Protein
abx060654-1mg 1 mg
EUR 2030.4

SARS-CoV Spike Protein
abx060655-1mg 1 mg
EUR 2030.4

SARS protein (His tag)
80R-2099 50 ug
EUR 386.4
Description: Recombinant human SARS protein (His tag)

SARS Protein Detection Set
PSI-1810 1 Set
EUR 884.4
Description: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral S (Spike) protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. The M protein (Membrane protein, Matrix protein) is another major structural viral protein. It is an integral membrane protein involved in the budding of the viral particles and interacts with S protein and the nucleocapsid protein. The SARS E protein contains a short palindromic transmembrane helical hairpin that seems to deform lipid bilayers, which may explain its role in viral budding and virion envelope morphogenesis. ACE2, the SARS receptor, normally plays a central role in vascular, renal, and myocardial physiology. In contrast to its homolog ACE, ACE2 expression is restricted to heart, kidney, and testis.;;For images please see PDF data sheet

Recombinant SARS Matrix Protein
VAng-Lsx0059-inquire inquire Ask for price
Description: SARS Matrix, recombinant protein from E. coli.

SARS Recombinant Protein (Human)
RP027604 100 ug Ask for price

SARS Recombinant Protein (Human)
RP027607 100 ug Ask for price

SARS Recombinant Protein (Rat)
RP227480 100 ug Ask for price

SARS Recombinant Protein (Mouse)
RP170009 100 ug Ask for price

SARS Recombinant Protein (Mouse)
RP170012 100 ug Ask for price

Peptidoglycan Recognition Protein-S (PGRP-S) Antibody
abx433127-200ul 200 ul
EUR 460.8

SARS Antibody, HRP conjugated
1-CSB-PA04145B0Rb
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against SARS. Recognizes SARS from Human. This antibody is HRP conjugated. Tested in the following application: ELISA

SARS Antibody, FITC conjugated
1-CSB-PA04145C0Rb
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against SARS. Recognizes SARS from Human. This antibody is FITC conjugated. Tested in the following application: ELISA

SARS Antibody, Biotin conjugated
1-CSB-PA04145D0Rb
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against SARS. Recognizes SARS from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA

SARS-CoV Spike Antibody
3219-002mg 0.02 mg
EUR 206.18
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
3219-01mg 0.1 mg
EUR 523.7
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
3221-002mg 0.02 mg
EUR 206.18
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
3221-01mg 0.1 mg
EUR 523.7
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
3223-002mg 0.02 mg
EUR 206.18
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
3223-01mg 0.1 mg
EUR 523.7
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
3225-002mg 0.02 mg
EUR 206.18
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
3225-01mg 0.1 mg
EUR 523.7
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Matrix Antibody
3527-002mg 0.02 mg
EUR 206.18
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).

SARS-CoV Matrix Antibody
3527-01mg 0.1 mg
EUR 523.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).

SARS-CoV Matrix Antibody
3529-002mg 0.02 mg
EUR 206.18
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).

SARS-CoV Matrix Antibody
3529-01mg 0.1 mg
EUR 523.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).

SARS-CoV Envelope Antibody
3533-002mg 0.02 mg
EUR 206.18
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication.

SARS-CoV Envelope Antibody
3533-01mg 0.1 mg
EUR 523.7
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication.

SARS virus Sn Antibody
abx032683-400ul 400 ul
EUR 627.6

SARS virus Sn Antibody
abx032683-80l 80 µl
EUR 343.2

SARS virus Sm Antibody
abx032684-400ul 400 ul
EUR 627.6

SARS virus Sm Antibody
abx032684-80l 80 µl
EUR 343.2

ACE2 (SARS Receptor) Antibody
abx032686-400ul 400 ul
EUR 627.6

ACE2 (SARS Receptor) Antibody
abx032686-80l 80 µl
EUR 343.2

Polyclonal SARS Matrix Antibody
APR11178G 0.1 mg
EUR 790.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SARS Matrix . This antibody is tested and proven to work in the following applications:

Polyclonal SARS Matrix Antibody
APG02976G 0.1 mg
EUR 790.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SARS Matrix . This antibody is tested and proven to work in the following applications:

Anti-SARS-E2 antibody
STJ98377 100 µl
EUR 280.8
Description: Mouse monoclonal to SARS-E2.

Anti-SARS-M antibody
STJ98378 100 µl
EUR 280.8
Description: Mouse monoclonal to SARS-M.

PLPro Antibody (SARS-CoV)
100863 250 µg
EUR 360
Description: Chicken polyclonal antibody recognizing the SARS-CoV Papain-like Protease (PLpro) as a 35 kDa protein. Purified from egg yolks. This antibody recognizes PLPro from both SARS-CoV-1 and SARS-CoV-2. Does not cross react with SARS-CoV 3CL protease.

Recombinant SARS Spike Mosaic S Protein (aa 12-53, 90-115, 171-203)
VAng-Lsx0055-inquire inquire Ask for price
Description: Recombinant SARS-CoV Spike protein containing 12-53, 90-115, 171-203 amino acids immunodominant regions was expressed in E. coli and purified by proprietary chromatographic technique.

Recombinant SARS Spike Mosaic S Protein (aa 1051-1076, 1121-1154, 1162-1190)
VAng-Lsx0057-inquire inquire Ask for price
Description: Recombinant SARS-CoV Spike protein containing 1051-1076, 1121-1154, 1162-1190 amino acids immunodominant regions was expressed in E. coli and purified by proprietary chromatographic technique.

Recombinant SARS-CoV-2 S1+S2 ECD (S-ECD) Protein with His-Tag
E80002-1 100 ul
EUR 848.1

SARS siRNA
20-abx932473
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

SARS siRNA
20-abx932474
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

SARS siRNA
20-abx904776
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

pENTR223-SARS
PVT12269 2 ug
EUR 469.2

"S" SARS-CoV-2 Spike Glycoprotein mRNA (10 µg, Transfection-ready)
CVD19-430A-1 10 µg
EUR 360
We show RhAd52 vaccines elicit sturdy SARS-CoV-2-specific antibody responses and defend in opposition to medical illness and viral replication within the lungs. Additional, binding and neutralizing antibody titers correlated with protecting efficacy. These information validate the MA10 mouse mannequin as a useful gizmo to display screen and research novel vaccine candidates, in addition to the event of RhAd52 vaccines for COVID-19.

RELATED ARTICLESMORE FROM AUTHOR

LEAVE A REPLY

Please enter your comment!
Please enter your name here